

Title: Transitioning from Biosimilar to Novel Biologics: different strategies for optimized Antibody Production

Dr. Sunit Maity

Director, Product Development

Zumutor Biologics Pvt Ltd

India

Abstract:

The global market for biosimilars and improved biologic products has undergone a fundamental shift in recent years with respect to patient need and regulatory dynamics. The global biopharmaceutical market is growing at a rapid pace, with biosimilars poised to command an increased share. Impending patent cliffs, growing pressures to reduce therapy costs and drying drug pipelines create a compelling case for biosimilars, attracting even pharma innovators and generic players. However, given the stringent regulatory requirements of highly similar and interchangeability required for a biosimilar, many sponsors turned their interest to biobetters/ novel biologics (NBE). We at Zumutor have developed two technology platforms that are used to identify new targets and develop innovative biological entities for the treatment of cancer and other serious diseases. We have successfully developed immuno-onco checkpoint modulators and those molecules are currently undergoing efficacy characterization with relevant mouse model. Exciting data obtained with those mAb molecules will be presented.